Tuesday, May 21, 2013 Last update: 5:34 PM
Company Tech News as it Breaks
Trade Events
NanoString Technologies, Inc.
News articles for NanoString Technologies, Inc.:
Monday, May 20, 2013
- NanoString Technologies Files Registration Statement with the Securities and Exchange Commission for an Initial Public OfferingNanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has filed a registration statement with the U.S. ... read more
Wednesday, May 15, 2013
- NanoString Technologies Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical OncologyNanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast ... read more
Thursday, May 2, 2013
- Study Results Show Prosigna™ Breast Cancer Prognostic Gene Signature Assay by NanoString Technologies Estimates Risk of Late Recurrence in Postmenopausal Hormone Receptor Positive Breast Cancer PatienNanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced results from two studies that are featured in ... read more
Wednesday, April 17, 2013
- NanoString Technologies Secures Option From The Broad Institute for Exclusive Worldwide License of Liver Cancer Gene SignatureNanoString® Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that it has secured an option to an ... read more
Wednesday, March 6, 2013
- NanoString Technologies Presents Positive Results from Multisite Analytical Validation Study of Prosigna™ Breast Cancer Prognostic Gene Signature AssayNanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that results presented at the 2013 United States ... read more
Tuesday, February 19, 2013
- NanoString Launches Its First Commercial Diagnostic Product in the European Union and IsraelNanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced it has launched its first commercial in vitro ... read more
Thursday, December 6, 2012
- NanoString Technologies Announces Positive Results From Second Validation Study of PAM50-based Breast Cancer AssayNanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced positive results from the second clinical ... read more
Monday, December 3, 2012
- NanoString Technologies Announces Presentation of Three Studies on PAM50-based Breast Cancer Assay at 2012 CTRC-AACR San Antonio Breast Cancer SymposiumNanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced that results from three studies of ... read moreNanoString Technologies Completes $15.3 Million Series E FinancingNanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced the completion of a $15.3 million ... read more